JOSE ANGEL GARCIA GARCIA

Prof. Dr. JOSE ANGEL GARCIA GARCIA

Pathology, Catholic University of Valencia San Vicente Martir, Valencia, Spain
orcid

Research Focus & Metrics

Academic Career Length

30Years (1997-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 January 2022 in Cancers
Verified
Journal Article
Open access
PDF file
MNMartín Núñez-Abad
Martín Núñez-Abad
SCSilvia Calabuig-Fariñas
Silvia Calabuig-Fariñas
MMMiriam Lobo de Mena
Miriam Lobo de Mena
STSusana Torres-Martínez
Susana Torres-Martínez
CGClara García González
Clara García González
CCCarlos Camps
Carlos Camps
Breast cancer constitutes the most common malignant neoplasm in women around the world. Approximately 12% of patients are diagnosed with metastatic stage, and between 5 and 30% of early or locally advanced BC patients will relapse, making it an incurable disease. PD-L1 ligation is an immune inhibitory molecule of the activation of T cells, playing a relevant role in numerous types of malignant tumors, including BC. The objective of the present review is to analyze the role of PD-L1 as a biomarker in the different BC subtypes, adding clinical trials with immune checkpoint inhibitors and their applicable results. Diverse trials using immunotherapy with anti-PD-1/PD-L1 in BC, as well as prospective or retrospective cohort studies about PD-L1 in BC, were included. Despite divergent results in the reviewed studies, PD-L1 seems to be correlated with worse prognosis in the hormone receptor positive subtype. Immune checkpoints inhibitors targeting the PD-1/PD-L1 axis have achieved great response rates in TNBC patients, especially in combination with chemotherapy, making immunotherapy a new treatment option in this scenario. However, the utility of PD-L1 as a predictive biomarker in the rest of BC subtypes remains unclear. In addition, predictive differences have been found in response to immunotherapy depending on the stage of the tumor disease. Therefore, a better understanding of tumor microenvironment, as well as identifying new potential biomarkers or combined index scores, is necessary in order to make a better selection of the subgroups of BC patients who will derive benefit from immune checkpoint inhibitors.

1 June 2001 in Journal of Clinical Pathology
Verified
Journal Article
Closed access
APA Pérez-Vallés
A Pérez-Vallés
MMM Martorell-Cebollada
M Martorell-Cebollada
ENE Nogueira-Vázquez
E Nogueira-Vázquez
JGJOSE ANGEL GARCIA GARCIA
JOSE ANGEL GARCIA GARCIA
EFE Fuster-Diana
E Fuster-Diana
Aim —To assess the value of immunohistochemistry in discriminating between BRCA1 associated and non-BRCA1 associated breast tumours. Methods —Four commercially available anti-BRCA1 antibodies were used on 45 paraffin wax embedded tumoral samples from patients with (seven of 45) and without (38 of 45) BRCA1 germline mutations. In all patients, the BRCA1 gene had been studied previously by means of the protein truncation test (PTT), conformational sensitive gel electrophoresis (CSGE), and direct sequencing of genomic DNA. Immunohistochemistry was carried out using the standard avidin–biotin immunoperoxidase method. Antigen retrieval was carried out by means of microwave pretreatment or autoclaving. The antibody panel used comprised D-20 (1/500), I-20 (1/100), K-18 (1/100), and MS110 (Ab-1; 1/50). Results —No immunohistochemical differences in BRCA1 protein expression were found between cases with and without BRCA1 germline mutations. All positive cases showed predominantly cytoplasmic staining, in both tumoral and non-tumoral cells, with the polyclonal antibodies D-20, I-20, and K-18. After heating pretreatment both nuclear and cytoplasmic staining were found in tumoral and non-tumoral cells with the I-20 antibody. Only the monoclonal antibody MS110 showed a predominantly nuclear staining after microwave oven treatment. Conclusions —Commercially available BRCA1 antibodies lack the specificity required to identify the BRCA1 protein and thus are not useful for establishing differences between familial and sporadic breast tumours, or between BRCA1 associated and non-BRCA1 associated breast tumours.

31 January 2021 in Therapeutic Advances in Medical Oncology
Verified
Journal Article
Open access
PDF file
MAMartín Núñez Abad
Martín Núñez Abad
SCSilvia Calabuig-Fariñas
Silvia Calabuig-Fariñas
MMMiriam Lobo de Mena
Miriam Lobo de Mena
MBMaría José Godes Sanz de Bremond
María José Godes Sanz de Bremond
CGClara García González
Clara García González
CHCarlos Camps Herrero
Carlos Camps Herrero
Triple negative breast cancer (TNBC) is a heterogeneous disease representing about 15% of all breast cancers. TNBC are usually high-grade histological tumors, and are generally more aggressive and difficult to treat due to the lack of targeted therapies available, and chemotherapy remains the standard treatment. There is a close relationship between pathological complete response after chemotherapy treatment and higher rates of disease-free survival and overall survival. In this review of systemic treatment in early triple negative breast cancer, our purpose is to analyze and compare different therapies, as well as to highlight the novelties of treatment in this breast cancer subtype.

18 June 2007 in Diagnostic Pathology
Verified
Journal Article
Open access
PDF file
MMMiguel Martorell
Miguel Martorell
APAna Pérez-Vallés
Ana Pérez-Vallés
FGFrancisco Gozalbo
Francisco Gozalbo
JGJOSE ANGEL GARCIA GARCIA
JOSE ANGEL GARCIA GARCIA
JHJair Manuel Gutiérrez Herrera
Jair Manuel Gutiérrez Herrera
JGJohn Gaona
John Gaona
Background: Extrapleural Solitary Fibrous tumors (SFTs) have been increasingly reported. The retroperitoneum, deep soft tissues of proximal extremities, abdominal cavity, trunk, head and neck are the most common extraserosal locations reported. Microscopically they show a wide range of morphological features, and so the differential diagnosis is extensive. Immunohistochemically, they commonly express CD34, vimentin, bcl-2 and CD99. Epithelial membrane antigen (EMA) and smooth muscle actin (SMA) may occasionally be expressed. Epithelioid morphology in extrapleural SFT has only very occasionally been described (five cases reported), some of them with biphasic pattern and others with malignant characteristics. Case presentation: A SFT of the thigh with epithelioid areas in a 63 year old woman is reported. Microscopically the tumor showed areas hypo and hipercellular. At the periphery of the hipercellular areas there were nodules composed of epithelioid cells. Immunohistochemically both the spindle and epithelioid cells were positive for CD34, vimentin, bcl-2 and CD99. Epithelial, neural and muscular markers were negative. Molecular study was done and ruled out a synovial sarcoma. Conclusion: Ten cases of SFT of the thigh have been reported but to our knowledge this is the first case with epithelioid morphology affecting the extremities. Identification of this pattern of SFT is of importance, to avoid misdiagnosis with other more aggressive conditions in soft tissue.

21 June 2010 in Diagnostic Pathology
Verified
Journal Article
Open access
PDF file
COCristian Ortiz-Villalón
Cristian Ortiz-Villalón
TITetsuo Ito
Tetsuo Ito
YHYosuke Hashimoto
Yosuke Hashimoto
SNSatoshi Nagayama
Satoshi Nagayama
AIAkira Iwai
Akira Iwai
YSYutaka Shimada
Yutaka Shimada
Fascin induces membrane protrusions and cell motility. Fascin overexpression was associated with poor prognosis, and its downregulation reduces cell motility and invasiveness in esophageal squamous cell carcinoma (ESCC). Using a stable knockdown cell line, we revealed the effect of fascin on cell growth, cell adhesion and tumor formation.

1 September 2005 in Archives of Pathology & Laboratory Medicine
Verified
Journal Article
Closed access
MMMiguel Martorell
Miguel Martorell
MGManuel Gil-Salom
Manuel Gil-Salom
APAna Pérez-Vallés
Ana Pérez-Vallés
JGJOSE ANGEL GARCIA GARCIA
JOSE ANGEL GARCIA GARCIA
NRNuria Rausell
Nuria Rausell
ASAlejo Senpere
Alejo Senpere
Human papillomavirus (HPV) plays a major role in the etiology of many malignancies of diverse localization, such as uterine cervical carcinoma and its precursors. Human papillomavirus sequences have been detected throughout the male lower genitourinary tract, but the role of men as transmitters remains unclear. To investigate the relationship between azoospermia and the presence of HPV DNA in testicular cells. One hundred eighty-five patients with azoospermia undergoing testicular biopsy were studied. Histologic study was done on formalin-fixed, paraffin-embedded samples from testicular biopsies, stained with hematoxylin-eosin. Molecular study to detect HPV sequences was performed on genomic DNA isolated from paraffin sections by standard protocols. Seven cases containing HPV sequences were studied after microdissection with PALM microlaser technology in order to determine the presence of HPV DNA sequences in different cells, as well as from seminal tubules or stromal (Leydig) cells. Human papillomavirus DNA sequences were detected in testicular biopsies of 12 patients (6.48%). Human papillomavirus type 16 was the most common genotype encountered. Among the 92 patients who underwent bilateral testicular biopsy, HPV sequences were detected in 9 patients (9.78%), all of whom showed only unilateral testicular affection, more often in the left testicle (ratio, 2: 1). After microdissection, HPV DNA sequences were seen in Leydig and Sertoli cells; the presence of HPV in germinal cells could not be ruled out. Leydig cells, Sertoli cells, and probably germinal cells (cases 2, 3, and 4) harbored HPV DNA sequences. Such findings have not been previously described in testicular tissue.